Abstracts tion cost compared to generic risperidone. CONCLUSIONS: Treatment of early responders was more cost-effective than the treatment of early non-responders to atypical antipsychotic therapy. The treatment of early non-responders who switched to olanzapine was more cost-effective than treatment of early non-responders maintained on generic risperidone. OBJECTIVES: The purpose was to conduct an economic analysis of escitalopram (generic drug) versus sertraline and venlafaxine as standard regimen in treatment of major depressive disorder (MDD) in Poland. METHODS: Due to lack of statistically significant differences in comparisons of escitalopram with sertraline and escitalopram with venlafaxine, economic profitability estimation was conducted as a cost-minimisation analysis (CMA). Decision model was created by using TreeAge® Pro. Data concerning efficacy and safety of compared therapies was based on the clinicaleffectiveness analysis, which was conducted as systematic literature review. Total costs of analysed therapies were estimated from the perspective of both payers in Poland (National Health Fund and patient) and also from the social perspective. The time horizon of the analysis was 6 months. The costs were not discounted. The stability of results was checked in one-way and probabilistic sensitivity analyses. Additionally, optimistic and pessimistic scenarios were prepared. RESULTS: Based on the assumptions that clinical effects of compared treatment strategies are the same, the results of the cost-minimisation analysis are as following: treatment of one patient using escitalopram in the 6 month time horizon is 12.71 PLN more expensive then sertraline therapy and 135.95 PLN cheaper then therapy with venlafaxine. One-way sensitivity analysis conducted for comparison of escitalopram versus sertraline showed that results are sensitive on the prices of medicaments. The sensitivity analysis conducted for comparison of escitaloprom versus venlafaxine showed the stability of basic results. Therapy with escitalopram is cheaper than with venlafaxine for all parameters took into account in the sensitivity analysis. CONCLUSIONS: Escitalopram (generic drug) is costly comparable to sertraline and cheaper option of treatment in comparison with venlafaxine in the treatment of major depressive disorder in the 6 month time horizon. OBJECTIVES: Opioid addiction is a chronic brain disease with severe withdrawal symptoms and decompensated condition in the vicious circle of compulsive drug seeking behavior, including needle sharing, psychosocial dysfunction, and criminal acts due to financial decompensation. Methadone maintenance therapy is the service under the concept of harm reduction. We analyzed the estimated utility of prevention in the implementation of methadone maintenance therapy introduced in Taiwan since 2006. METHODS: By using the methadone registry data and the estimation of incidence rates of decompensation with versus without methadone maintenance, the expected number of decompensated cases reduced by harm reduction can be calculated. The utility possibly gained is estimated based on assumption of different values of quality of life (QOL) for the decompensation. RESULTS: Based on the imprisoned registry of Ministry of Justice and estimations of the Center for Diseases Control, the number of heroin addicts in Taiwan was about 100,000, with a total of 15,000 regularly in prison. The yearly number of methadone registry cases reached 15,500 by the year-end of 2008. Assuming that annual incidence rates of decompensation were about 0.1 and 0.7 for heroin addicts with and without methadone therapy, then the annual expected number prevented by such treatments would be 9000 with a possible gain of utility of 1800 and 4500 QALY (quality-adjusted life year), respectively, depending on the reduced utility of 0.2-0.5 for the QOL among decompensated cases. CONCLU-SIONS: As the annual cost for administration of methadone program was about 40,000 NTD, which leads to an incremental cost of 66,640 to 166,600 NTD (1 USD = 32 NTD) per QALY, without counting the cost of possible harm produced to the society by decompensated behaviors. With improved accessibility of methadone maintenance therapy, the utility of prevention for the decompensation of heroin addiction may be further increased. OBJECTIVES: Major depressive disorder (MDD) is a psychiatric condition principally characterized by depressive mood, loss of appetite, decreased interest in daily activities, sleep, behavioural or attentional disorders, diminution of energy, and feelings of guilt. Because MDD is associated with substantial health care costs and productivity losses, it wields a considerable economic impact. The aim of this study was to assess, in the Canadian context, the economic impact of escitalopram in the treatment of MDD. METHODS: A cost-utility analysis was performed over a one-year time horizon from societal and health care system perspectives in Canada. A decision tree was developed to compare the cost per quality adjusted life year (QALY) associated with the use of escitalopram and citalopram. The decision tree, which included patients with MDD who had received escitalopram or citalopram as initial treatment, takes into account the probability of initial and subsequent treatment remission, of relapse, of suicide attempts, and of suicide-related death. Costs included were those of the antidepressant drugs, medical visits and hospitalizations, and those associated with remission/nonremission, relapses, suicide attempts and suicide-related deaths. Costs related to productivity loss and societal costs associated with suicide-related deaths were also included in the analysis with the societal perspective. Utility values associated with remission and non-remission were obtained from the literature. RESULTS: From a health care perspective, the incremental cost-utility ratio of escitalopram compared to citalopram was estimated at $12,869/QALY. From a societal perspective, escitalopram provided more QALYs (+0.0085 QALY/patient) and entailed fewer costs (−$144.70/ patient) compared to citalopram. Deterministic and probabilistic sensitivity analyses confirmed the robustness of the base-case results. CONCLUSIONS: The results of this economic evaluation indicate that escitalopram is a more cost-effective alternative than citalopram to treat MDD from both the health care system and societal perspectives.
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PMH52 ECONOMIC ANALYSIS OF ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD)
Walczak J, Nogas G, Garbacka M, Obrzut G, Pieniazek I Arcana Institute, Cracow, Poland OBJECTIVES: The purpose was to conduct an economic analysis of escitalopram (generic drug) versus sertraline and venlafaxine as standard regimen in treatment of major depressive disorder (MDD) in Poland. METHODS: Due to lack of statistically significant differences in comparisons of escitalopram with sertraline and escitalopram with venlafaxine, economic profitability estimation was conducted as a cost-minimisation analysis (CMA). Decision model was created by using TreeAge® Pro. Data concerning efficacy and safety of compared therapies was based on the clinicaleffectiveness analysis, which was conducted as systematic literature review. Total costs of analysed therapies were estimated from the perspective of both payers in Poland (National Health Fund and patient) and also from the social perspective. The time horizon of the analysis was 6 months. The costs were not discounted. The stability of results was checked in one-way and probabilistic sensitivity analyses. Additionally, optimistic and pessimistic scenarios were prepared. RESULTS: Based on the assumptions that clinical effects of compared treatment strategies are the same, the results of the cost-minimisation analysis are as following: treatment of one patient using escitalopram in the 6 month time horizon is 12.71 PLN more expensive then sertraline therapy and 135.95 PLN cheaper then therapy with venlafaxine. One-way sensitivity analysis conducted for comparison of escitalopram versus sertraline showed that results are sensitive on the prices of medicaments. The sensitivity analysis conducted for comparison of escitaloprom versus venlafaxine showed the stability of basic results. Therapy with escitalopram is cheaper than with venlafaxine for all parameters took into account in the sensitivity analysis. CONCLUSIONS: Escitalopram (generic drug) is costly comparable to sertraline and cheaper option of treatment in comparison with venlafaxine in the treatment of major depressive disorder in the 6 month time horizon.
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ESTIMATION OF UTILITY GAINED FROM METHADONE MAINTENANCE TREATMENT FOR OPIOID DEPENDENCE
Liao DL 1 , Wang JD 1 , Huang CY 2 , Chen PC 3 1 National Taiwan University, Taipei, Taiwan, 2 Bali Psychiatric Center, Taipei, Taiwan, 3 National Taiwan University, Taipei, Taiwan OBJECTIVES: Opioid addiction is a chronic brain disease with severe withdrawal symptoms and decompensated condition in the vicious circle of compulsive drug seeking behavior, including needle sharing, psychosocial dysfunction, and criminal acts due to financial decompensation. Methadone maintenance therapy is the service under the concept of harm reduction. We analyzed the estimated utility of prevention in the implementation of methadone maintenance therapy introduced in Taiwan since 2006. METHODS: By using the methadone registry data and the estimation of incidence rates of decompensation with versus without methadone maintenance, the expected number of decompensated cases reduced by harm reduction can be calculated. The utility possibly gained is estimated based on assumption of different values of quality of life (QOL) for the decompensation. RESULTS: Based on the imprisoned registry of Ministry of Justice and estimations of the Center for Diseases Control, the number of heroin addicts in Taiwan was about 100,000, with a total of 15,000 regularly in prison. The yearly number of methadone registry cases reached 15,500 by the year-end of 2008. Assuming that annual incidence rates of decompensation were about 0.1 and 0.7 for heroin addicts with and without methadone therapy, then the annual expected number prevented by such treatments would be 9000 with a possible gain of utility of 1800 and 4500 QALY (quality-adjusted life year), respectively, depending on the reduced utility of 0.2-0.5 for the QOL among decompensated cases. CONCLU-SIONS: As the annual cost for administration of methadone program was about 40,000 NTD, which leads to an incremental cost of 66,640 to 166,600 NTD (1 USD = 32 NTD) per QALY, without counting the cost of possible harm produced to the society by decompensated behaviors. With improved accessibility of methadone maintenance therapy, the utility of prevention for the decompensation of heroin addiction may be further increased.
PMH54 ECONOMIC EVALUATION OF ESCITALOPRAM TO TREAT MAJOR DEPRESSIVE DISORDER
Lachaine J 1 , Beauchemin C 1 , Legault M 2 1 University of Montreal, Montreal, QC, Canada, 2 Lundbeck Canada Inc., Montreal, QC, Canada OBJECTIVES: Major depressive disorder (MDD) is a psychiatric condition principally characterized by depressive mood, loss of appetite, decreased interest in daily activities, sleep, behavioural or attentional disorders, diminution of energy, and feelings of guilt. Because MDD is associated with substantial health care costs and productivity losses, it wields a considerable economic impact. The aim of this study was to assess, in the Canadian context, the economic impact of escitalopram in the treatment of MDD. METHODS: A cost-utility analysis was performed over a one-year time horizon from societal and health care system perspectives in Canada. A decision tree was developed to compare the cost per quality adjusted life year (QALY) associated with the use of escitalopram and citalopram. The decision tree, which included patients with MDD who had received escitalopram or citalopram as initial treatment, takes into account the probability of initial and subsequent treatment remission, of relapse, of suicide attempts, and of suicide-related death. Costs included were those of the antidepressant drugs, medical visits and hospitalizations, and those associated with remission/nonremission, relapses, suicide attempts and suicide-related deaths. Costs related to productivity loss and societal costs associated with suicide-related deaths were also included in the analysis with the societal perspective. Utility values associated with remission and non-remission were obtained from the literature. RESULTS: From a health care perspective, the incremental cost-utility ratio of escitalopram compared to citalopram was estimated at $12,869/QALY. From a societal perspective, escitalopram provided more QALYs (+0.0085 QALY/patient) and entailed fewer costs (−$144.70/ patient) compared to citalopram. Deterministic and probabilistic sensitivity analyses confirmed the robustness of the base-case results. CONCLUSIONS: The results of this economic evaluation indicate that escitalopram is a more cost-effective alternative than citalopram to treat MDD from both the health care system and societal perspectives.
PMH55 CANADIAN COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE VERSUS ORAL ATYPICAL AND CONVENTIONAL DEPOT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA AT HIGH-RISK OF NON-COMPLIANCE: UPDATED BASED ON NEW CLINICAL DATA
Lam A 1 , Heeg B 2 1 Janssen-Ortho Inc., Toronto, ON, Canada, 2 Pharmerit Europe, Rotterdam, The Netherlands OBJECTIVES: The Canadian cost-effectiveness analysis of long-acting risperidone versus oral atypical and conventional depot antipsychotics in the treatment of schizophrenia was updated based on results from a study comparing long-acting risperidone to depot zuclopenthixol. METHODS: An extensive pharmacoeconomic discrete event model was developed to estimate the costs and health benefits of patients treated with long-acting risperidone versus oral atypical and conventional depot antipsychotics in the treatment of patients with schizophrenia at high-risk of non-compliance over a five-year period. In the original analysis, oral risperidone was considered in the oral atypical arm and haloperidol decanoate was considered in the conventional depot arm. At the time of the original analysis there were no head-to-head clinical studies which compared long-acting risperidone to conventional depots. Since, an open-label, randomized, controlled, assessor-blinded, six-month study comparing long-acting risperidone to depot zuclopenthixol has been published. Using these study results, the model was updated to consider depot zuclopenthixol as the treatment for the depot comparator arm. The comparator of oral risperidone for the oral atypical arm remained the same. RESULTS: The model projected the five-year cumulative direct costs of $155,601, $178,153, and $182,942 (discounted) for long-acting risperidone, oral risperidone, and depot zuclopenthixol, respectively. Thus, treatment with long-acting risperidone saved approximately $22,552 and $27,341 (discounted) over 5 years compared to oral risperidone and depot zuclopenthixol. Moreover, long-acting risperidone resulted in greater decreases in the number of relapses, total time spent in psychosis and a greater increase in quality-adjusted-life-years (QALYs) compared to oral risperidone or depot zuclopenthixol. Hence, long-acting risperidone is the dominant strategy, being more effective and less costly than oral risperidone or depot zuclopenthixol. CONCLUSIONS: Consistent with the original analysis, the current analysis demonstrates that long-acting risperidone is a cost-effective option which results in better clinical outcomes and lower total health care costs than oral risperidone or depot zuclopenthixol.
PMH56 ADULT ATTENTION DEFICIT HYPERACTIVITY DISORDER, LABOR FORCE STATUS AND WORKPLACE ABSENTEEISM AND PRESENTEEISM
Langley PC 1 , Wagner JS 2 , DiBonaventura MD 3 1 University of Minnesota, Minneapolis, MN, USA, 2 KantarHealth, Princeton, NJ, USA, 3 KantarHealth, New York, NY, USA OBJECTIVES: This analysis considers the impact of ADHD in adults on 1) labor force status, and 2) workplace absenteeism and presenteeism in the US. METHODS: Data from the 2009 US National Health and Wellness Survey (NHWS) were used to identify all those in the labor force 18 to 49 years of age with a diagnosis of attention deficit disorder (ADD) or ADHD. The analysis was in two stages: 1) an evaluation of the prevalence of adult ADHD (n = 40,428), and 2) the estimation of logistic regressions to assess the contribution of unmedicated/medicated ADHD to labor force status and the estimation of ordered probit regressions (n = 25,862) to assess the contribution of unmedicated/medicated ADHD to absenteeism and presenteeism. Additional variables that are considered are socio-demographic status and health risk factors, together with the Charlson Comorbidity Index (CCI). RESULTS: An estimated 2.7% had diagnosed ADHD. This had a significant negative impact on labor force participation (odds ratio 0.817), although medicated ADHD had no impact. The presence of unmedicated ADHD and medicated ADHD were, however, significant at the 1% level in both the absenteeism and presenteeism models. Odds ratios in the absenteeism model were 4.79 for those with unmedicated ADHD and 3.27 for those with medicated ADHD. These were of a similar magnitude to odds ratios for health risk factors (obesity 3.40 and morbid obesity 6.34) but less than the CCI odds ratio 17.43. In the presenteeism model, the odds ratios were also significant at the 1% level at 8.07 for medicated and 6.99 for unmedicated ADHD. CONCLUSIONS: The presence of unmedicated, ADHD in adults has a negative impact on labor force participation in the US. Irrespective of whether or not the ADHD is medicated, its presence also has a significant impact on increased absenteeism and presenteeism.
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PSYCHIATRIC-RELATED HEALTH CARE COSTS AND RISK OF HOSPITALIZATION AMONG MEDICAID PATIENTS WITH TYPE I BIPOLAR DISORDER WHO RELAPSE FREQUENTLY
Durden E 1 , Muser E 2 , Choi J 3 , Bagalman E 4 , Dirani R 3 1 Thomson Reuters, Austin, TX, USA, 2 Ortho-McNeil Janssen Scientific Affairs, LLC, O'Fallon, MO, USA, 3 Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 4 Thomson Reuters, Washington, DC, USA OBJECTIVES: To examine psychiatric-related health care costs and inpatient utilization among patients with type I bipolar disorder who relapse frequently within a large Medicaid database. METHODS: A large multistate Medicaid claims database (Mar-ketScan ® ) was used to identify patients aged 18 to 64 years with type I bipolar disorder; ≥1 prescription claim for lithium, an anticonvulsant, or an antipsychotic between January 1, 2004 and December 31, 2005; and ≥24 months' continuous enrollment. Frequent relapse (FR) was defined as ≥2 clinically significant events (CSEs) occurring during a 12-month identification period beginning with the initial CSE (if any). CSEs included emergency room (ER) visits or inpatient hospitalizations (IH) with a principal diagnosis of bipolar disorder or a change in bipolar disorder medication(s). Patients were followed for a subsequent 12-month period to evaluate health care utilization and associated costs. Generalized linear modeling was used to estimate the impact of FR on psychiatric-related health care costs; logistic regression was used to estimate the impact of FR on psychiatric IH and ER visits. RESULTS: Of 5527 patients with type I bipolar disorder, 53% relapsed frequently. Of the patients with FR, 75% were female. Close to one-third (29%) of patients who relapsed frequently in the identification period also relapsed frequently in the follow-up period. During the 12-month follow-up period, patients with FR had higher adjusted per-patient psychiatric-related health care costs (mean $6014 vs $3495; P < 0.001), 3.7 times greater odds of psychiatric IH (P < 0.01), and 3.1 times greater odds of psychiatric-related ER visits (P < 0.01) than patients who did not relapse frequently. CONCLUSIONS: Medicaid patients with type I bipolar disorder who relapsed frequently had significantly higher adjusted psychiatric-related health care costs and greater odds of IH and ER events in a subsequent period than patients who did not relapse frequently. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC. Retrospective cohort analysis of multistate Medicaid patients who were aged ≥18 years, had ≥1 inpatient or ≥2 outpatient medical claims indicating bipolar I disorder (ICD-9-CM codes 296.0X-296.1X, 296.4X-296.7X), and filled ≥1 prescription for an antipsychotic medication between January 1, 2004, and December 31, 2006. Patients were followed for 1 year from the date of first, or index, antipsychotic prescription. Patients were required to be continuously eligible for Medicaid without dual Medicare eligibility from 1 year before (baseline) through 1 year after (follow-up) index, and were required to receive ≥1 additional antipsychotic claim during follow-up to ensure a treated population. Descriptive statistics were generated on the use and costs (proxied by Medicaid payments) of hospitalizations and ER visits, both all-cause and psychiatric-related (ICD-9-CM 290.XX-319.XX). RESULTS: 9410 patients met study eligibility criteria. Mean (±SD) patient age was 38.0 (±11.9) years, 74% were female, and 75% were white. Approximately 31% and 57% had preexisting diagnoses of substance abuse and psychiatric conditions, respectively. During follow-up, 40% of patients were hospitalized for any reason (37% with a psychiatric diagnosis). Patients had an average (±SD) of 0.9 (±1.7) all-cause and 0.8 (±1.6) psychiatric-related hospitalizations. All-cause and psychiatric-related ER visits occurred in 67% and 29% of patients, with an average (±SD) of 6.1 (±10.9) and 0.9 (±2.7) visits per patient, respectively. Average (±SD) costs were $6986 (±$10,374) and $6916 (±$10,288) for all-cause and psychiatric-related hospitalizations, and $158 (±$218) and $256 (±$416) for all-cause and psychiatric-related ER visits, respectively. CONCLUSIONS: Hospitalizations, ER visits, and costs were substantial among patients with bipolar I disorder. Studies investigating predictors of hospitalizations and ER visits in this patient population are warranted. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC.
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ASSESSMENT OF HEALTH CARE UTILIZATION AND COST AMONG PATIENTS WITH BIPOLAR I DISORDER TREATED WITH ANTIPSYCHOTIC THERAPY IN A MULTISTATE MEDICAID POPULATION
PMH59 SYSTEM DYNAMICS SIMULATION FOR ACUTE SCHIZOPHRENIA TREATMENT
Nakahara N 1 , Kobayashi M 2 , Mano T 3 , Nakamura J 4 1 Eli Lilly Japan, Kobe, Japan, 2 Crecon Research & Consulting Inc., Tokyo, Japan, 3 Tama University of Medical Risk management Center, Tokyo, Japan, 4 University of Occupational and Environmental Health, Kitakyushu, Japan OBJECTIVES: It is important for the management of a psychiatric hospital having an acute-care ward to estimate medical practice revenues under different conditions. We developed a system dynamics (SD) simulation model for the treatment of acute schizophrenia to investigate the effect of the treatment of patients with acute schizophrenia on the hospital management. METHODS: We developed an SD simulation model for patient admission and discharge at a psychiatric acute-care ward. The model assumed an imaginary, newly built psychiatric hospital consisting of 3 types of wards: a psychiatric acute-care ward, a general psychiatric ward, and a psychiatric nursing-care ward. The rates of discharge were set at 40%/month, 30%/month and 20%/month for a psychiatric acute-care ward, a general psychiatric ward, and a psychiatric nursing-care ward, respectively. The number of newly admitted patients was supposed to be 10 per month. We compared the total medical practice revenues at 36 months. RESULTS: Up to 9 months of outpatient treatment, the total medical practice revenues increased and then decreased at 12 months. A 2-way sensitivity analysis on the firsttime admissions and the duration of outpatient treatment revealed that the total medical practice revenues were higher when the number of newly admitted patients was 5-11 at 9 months of outpatient management; however, when the number of newly admitted patients was 12-15, the maximum medical practice revenue was obtained at 12 months of outpatient management. CONCLUSIONS: Total medical practice revenues change depending on the rates of discharge from a psychiatric acute-care ward, the duration of outpatient treatment and the number of newly admitted patients. A budget plan for each psychiatric hospital having a psychiatric acute-care ward should be based on the calculation of those parameters and a systematic approach to patient management is important.
MENTAL HEALTH -Patient-Reported Outcomes Studies
PMH60 ADHERENCE TO MEDICATION FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD):DOES THE TIMEFRAME MATTER?
Barner JC, Khoza S, Oladapo A The University of Texas at Austin, Austin, TX, USA OBJECTIVES: ADHD medication users frequently take 'drug holidays' during the summer months. The study objective was to compare ADHD medication adherence for an entire year (EY-365 days) and the school year (SY-270 days) by medication class and type. METHODS: Continuously enrolled Texas Medicaid children (≤18 years) who had ≥2 prescription claims for an ADHD medication served as the study population. EY and SY (September 1-May 31) prescription claims were extracted from July 2002-December 2008. Prescription claims were grouped by medication class [immediate release(IR), extended release(ER), long-acting(LA), non-stimulant(NS)]; and medication type [stimulant(S) vs. non-stimulant(NS)]. Adherence, assessed by medication possession ratio (MPR) using a fixed interval denominator, was measured both continuously and dichotomously (80%). T-tests, ANOVAs and chi-square were employed to determine differences between groups. RESULTS: Overall mean adherence for EY (n = 62,789) was 49.8 ± 30.3 and SY (n = 50,842) was 62.2 ± 26.2. For EY, mean medication class adherence was not significantly different between NS (52.5 ± 30.9) and ER (52.1 ± 30.2); however, LA (47.6 ± 30.9) and IR (37.2 ± 27.1) were significantly lower (p < 0.0001). Regarding SY, adherence was not significantly different among ER (63.7 ± 26.0), LA (63.5 ± 23.8) and NS (62.9 ± 27.0), while IR (52.8 ± 24.7) was significantly lower (p < 0.0001). When adherence was dichotomized, EY medication class adherence differed significantly (p < 0.0001): NS(25.8%), ER(24.1%), LA(21.2%), IM(9.8%). Similarly, SY differed significantly (p < 0.0001): NS(30.8%), ER(30.0%), LA(25.6%), IM(16.2%). NS had significantly higher mean adherence than S, respectively: EY(52.5 ± 30.9 vs. 49.4 ± 30.2; p < .0001) and SY(62.9 ± 27.0 vs. 62.1 ± 26.1; p < .01). When dichotomized, results were similar (p < .0001): EY(25.8% vs. 21.5%) and SY(30.8% vs. 27.9%). CONCLUSIONS: Subjects were more adherent during SY compared to EY. Medication class mean adherence differed depending on timeframe used. For analyses comparing NS and S, NS had significantly higher adherence, however for SY mean adherence, the difference may not be practically significant. Due to unique patient medication-taking behaviors, ADHD medication adherence differs depending on the timeframe used.
